Therapy of birch pollen allergy by apple consumption (Q4296557)
Jump to navigation
Jump to search
No description defined
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Therapy of birch pollen allergy by apple consumption |
No description defined |
Statements
617,972.52 Euro
0 references
799,905.32 Euro
0 references
77.26 percent
0 references
1 January 2017
0 references
31 December 2019
0 references
Centro di Sperimentazione Agraria e Forestale Laimburg
0 references
46°22'57.43"N, 11°17'17.74"E
0 references
46°29'56.51"N, 11°18'26.89"E
0 references
47°15'46.73"N, 11°23'3.91"E
0 references
47°15'40.57"N, 11°22'59.95"E
0 references
In Central Europe, 20% of the population are affected by pollen allergy. This percentage is rising steadily, also in Tyrol and South Tyrol. An efficient therapy consists of a long-term hyposensibilisation against the birch pollen allergen Bet v1 by pluriennal uptake of synthetic compounds, in order to adapt the human immune system to Bet v1. In comparison, it would be of upmost advantage to induce a hyposensibilisation through simple uptake of food. Due to their highly similar composition and structure, the birch pollen allergen Bet v1 and the apple allergen Mal d1 cause a strong cross-reaction in the human body. This cross-reaction provides an opportunity to use apples in a controlled and established dosage to cure pollen allergy. A transnational approach combining different research competences in medicine, molecular biology and structural chemistry will identify those apple varieties and dosages that are necessary for a successful therapy of pollen allergy. This interdisciplinary synergy will be used to establish an interregional database of allergy patients and to identify those fruits that are best suited for both a low-allergen diet and as a sustainable remedy for allergies. Last but not least, these results will promote the cross-border innovation potential. (English)
0 references